LSD is being investigated for anxiety that persists despite ordinary treatment and disrupts daily life. The clinical aim is a sustained reduction in worry, tension and impairment after a limited number of supervised administrations. Encouraging findings now extend beyond small psychotherapy studies, although the treatment’s long acute effects, safety requirements and longer-term place in care remain important questions.
A powerful experience is not itself evidence that an anxiety disorder has improved. Meaningful benefit concerns what happens afterwards: less persistent worry, better sleep and functioning, and a reduced need to organise life around avoidance.
On this page
Which kind of anxiety is being treated?
Generalised anxiety disorder involves excessive, difficult-to-control worry extending across everyday concerns. Anxiety associated with a life-threatening illness may have a different pattern and meaning. Panic disorder, PTSD and obsessive–compulsive disorder also require their own assessment. Findings in one of these populations should not be treated as evidence for all anxiety presentations.
Before considering any new intervention, the clinician needs to understand symptom duration, functional impairment, depression, substance use, physical illness and previous treatment. A person who remains anxious after an inadequate or poorly tolerated treatment course may need a revised care plan rather than the conclusion that every established option has failed.1
LSD, or lysergide, is a classical serotonergic psychedelic. Its acute effects can alter perception, emotion and the experience of self and surroundings. A temporary alteration in experience could create opportunities for psychological change, but that possibility does not identify which patient will benefit or whether improvement will last.
What controlled treatment has shown
A 2025 trial randomised 198 adults with moderate or severe generalised anxiety disorder to a pharmaceutical LSD formulation, MM120, at four dose levels or placebo. At four weeks, the two higher-dose groups showed significantly greater anxiety reduction than placebo; the two lower-dose groups did not. The findings support a dose-dependent effect under the study conditions, rather than a claim that any exposure is effective.2
An earlier trial in 42 patients with anxiety, with or without a life-threatening illness, used LSD-assisted therapy and a crossover design. Anxiety improved more after LSD over the first treatment period, with assessment extending to 16 weeks. The first-period comparison was particularly important because effects carried over into the later period.3
A smaller 2014 pilot involved 12 people with anxiety associated with life-threatening diseases. Its results helped establish the feasibility of studying this approach, but such a small sample cannot provide precise estimates of benefit or uncommon harms.4
These findings concern defined preparations, selected participants and supervised care. They do not establish that LSD is superior to established psychological treatment or medication in a direct comparison. Differences between trials in participants, support, outcome measures and follow-up also prevent a reliable ranking based on the size of the reported changes alone.
What the newer phase 3 announcements add
In August 2026, Definium Therapeutics reported positive results from its Voyage study of DT120, an orally disintegrating lysergide formulation. The sponsor reported 214 participants and a 5.4-point advantage over placebo on the Hamilton Anxiety Rating Scale at week 12. In September, its Panorama announcement reported a 5.1-point advantage for the principal active-versus-placebo comparison at the same time point.56
These are sponsor-reported topline results, cited here as such. They add relevant contemporary information, but require assessment alongside complete methods, missing-data analyses, adverse-event details and full trial reports. A positive announcement is not equivalent to a prescribing recommendation.
The distinction between response and remission remains important. In Panorama, the sponsor reported response in 32% of the principal active group and 14% of the placebo group, while remission was reported in 15% and 4%, respectively. Many participants therefore did not reach remission even in a positive study.6
| Outcome | Clinical meaning | Limit |
|---|---|---|
| Average symptom reduction | The group improved on a defined measure | Does not mean every participant benefited |
| Response | A specified proportional reduction in symptoms | Substantial symptoms may remain |
| Remission | Symptoms below the chosen threshold | Does not establish permanent recovery |
| Reduced functional impairment | Daily life becomes more manageable | Requires measurement beyond the acute experience |
Support without assuming a single psychotherapy model
The 2025 MM120 trial did not include a protocol-defined psychotherapeutic intervention. It did include two session monitors and a controlled setting. This distinction matters: the absence of a formal therapy model does not mean the absence of interpersonal support, clinical screening or observation.2
Other LSD studies combined administration with preparation and therapeutic conversations. The two approaches ask different questions about the treatment package. A benefit observed without a specified psychotherapy does not establish that support is dispensable, while benefit during a combined programme does not identify the contribution of each component.
Patients also differ in what they need afterwards. Some may want to discuss emotionally significant material; others may primarily require help with persistent worry, sleep or functioning. Support should respond to those needs without prescribing a particular spiritual narrative.7
The practical burden of a long session
In the 2025 MM120 trial, participants remained at the study site for 12 hours after administration.2 This makes the intervention more than a brief appointment. Assessment, supervision, travel arrangements and recovery time can all affect whether a treatment is manageable for a particular person.
Newer formulations and protocols should be evaluated on their own observed course. The Panorama announcement described a minimum eight-hour monitoring period and structured assessments of readiness to end the session.6 Meeting a study discharge checklist is a specific protocol outcome; it should not be converted into a universal prediction about when anyone will be ready to resume ordinary responsibilities.
Duration is also distinct from intensity. A person may find a prolonged altered state tiring or frightening even when later symptom improvement occurs. Informed choice requires discussing that burden before treatment rather than presenting the session only as an opportunity for insight.
Adverse effects and uncertain generalisability
Perceptual changes, nausea and headache were common in the MM120 trial, and participants frequently recognised their active-treatment allocation.2 Expectation can therefore influence how both the experience and subsequent change are understood.
The 42-person LSD-assisted therapy trial reported one treatment-related serious adverse event involving acute, transient anxiety.3 An intervention intended to reduce anxiety can still provoke intense anxiety during administration. Clinical supervision needs to include a capacity to assess and respond to distress, rather than assuming that every difficult experience should simply be endured.
Evidence from screened adults cannot automatically establish safety in people with unstable psychiatric illness, significant medical vulnerability or interacting medication regimens. Persistent sleep disturbance, unusual beliefs, severe anxiety or impaired functioning after an exposure require clinical assessment. They should not be interpreted solely through an expectation of therapeutic transformation.
Durability and continuing care
A planned follow-up of the earlier crossover trial obtained questionnaires from 39 participants one year after its end-of-study visit. Anxiety remained reduced relative to baseline. However, everyone had received LSD, outcomes were self-reported and intervening care was not fully characterised. The findings support the possibility of sustained improvement without proving that the original intervention alone caused it.8
NICE’s established care pathway for generalised anxiety disorder includes CBT, applied relaxation and medication options, selected according to clinical need and preference. If one approach has not helped, another can be considered.1 Interest in LSD should not close off continuing treatment while evidence and access arrangements develop.
Follow-up should address whether worry is less dominant, daily activity has expanded and improvements remain useful under ordinary stress. If symptoms return, reassessment is more informative than assuming that another psychedelic session is required. The long-term aim is sustained functioning with a workable care plan, not repeated pursuit of an exceptional experience.
References
- National Institute for Health and Care Excellence. Generalised anxiety disorder and panic disorder in adults: management (CG113). Recommendations; accessed 11 October 2026.
- Robison R, et al. Single Treatment With MM120 (Lysergide) in Generalized Anxiety Disorder: A Randomized Clinical Trial. JAMA. 2025;334:1358–1372. doi:10.1001/jama.2025.13481.
- Holze F, Gasser P, Müller F, et al. Lysergic Acid Diethylamide–Assisted Therapy in Patients With Anxiety With and Without a Life-Threatening Illness: A Randomized, Double-Blind, Placebo-Controlled Phase II Study. Biol Psychiatry. 2023. doi:10.1016/j.biopsych.2022.08.025.
- Gasser P, Holstein D, Michel Y, et al. Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. J Nerv Ment Dis. 2014;202:513-520. doi:10.1097/nmd.0000000000000113.
- Definium Therapeutics. Positive topline results from the phase 3 Voyage study of DT120 ODT in generalised anxiety disorder. Sponsor announcement, 12 August 2026; SEC filing exhibit 99.1.
- Definium Therapeutics. Positive topline results from the phase 3 Panorama study of DT120 ODT in generalised anxiety disorder. Sponsor announcement, 14 September 2026; SEC filing exhibit 99.1.
- Gorman I, Nielson EM, Molinar A, et al. Psychedelic Harm Reduction and Integration: A Transtheoretical Model for Clinical Practice. Front Psychol. 2021;12:645246. doi:10.3389/fpsyg.2021.645246.
- Holze F, Gasser P, Müller F, et al. LSD-assisted therapy in patients with anxiety: open-label prospective 12-month follow-up. Br J Psychiatry. 2024;225:362-370. doi:10.1192/bjp.2024.99.